The existing evidence strongly emphasizes the remarkable ability of TLSs to distinguish between responders to anti-PD1/PDL1 therapy, offering a pivotal mechanism for effectively modulating the tumor microenvironment in cancer immunotherapies. This evidence concerns the gene CD274 and neoplasm.